ecrin-mdr-crcClinical2021Colorectal CancerColorectal NeoplasmsIPD Sharing (as of March 2022): NoColorectal CancerColorectal NeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/2383996China11ECRIN MDRRecruitingfalseAnlotinib Plus Penpulimab (AK105) for Chemo-refractory Metastatic Colorectal Cancer:ALTER-C003A single-arm, open-label clinical trial, focus on the safety and efficacy of anlotinib hydrochloride in combination with Penpulimab (AK105) in patients with Chemo-refractory Metastatic Colorectal Cancer (mCRC)2021-11-152383996NCT04970914